Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy

NCT02572167 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT02572167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02572167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
Lead sponsor
Seagen Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2015
Completion date
October 21, 2021
Enrollment
93 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma